1. Home
  2. AKTX vs IRD Comparison

AKTX vs IRD Comparison

Compare AKTX & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • IRD
  • Stock Information
  • Founded
  • AKTX N/A
  • IRD 2018
  • Country
  • AKTX United States
  • IRD United States
  • Employees
  • AKTX N/A
  • IRD N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • AKTX Health Care
  • IRD
  • Exchange
  • AKTX Nasdaq
  • IRD NYSE
  • Market Cap
  • AKTX 37.6M
  • IRD 56.2M
  • IPO Year
  • AKTX N/A
  • IRD N/A
  • Fundamental
  • Price
  • AKTX $1.12
  • IRD $1.08
  • Analyst Decision
  • AKTX
  • IRD Strong Buy
  • Analyst Count
  • AKTX 0
  • IRD 3
  • Target Price
  • AKTX N/A
  • IRD $6.33
  • AVG Volume (30 Days)
  • AKTX 27.4K
  • IRD 754.1K
  • Earning Date
  • AKTX 08-18-2025
  • IRD 08-15-2025
  • Dividend Yield
  • AKTX N/A
  • IRD N/A
  • EPS Growth
  • AKTX N/A
  • IRD N/A
  • EPS
  • AKTX N/A
  • IRD N/A
  • Revenue
  • AKTX N/A
  • IRD $13,651,000.00
  • Revenue This Year
  • AKTX N/A
  • IRD $51.41
  • Revenue Next Year
  • AKTX N/A
  • IRD $68.84
  • P/E Ratio
  • AKTX N/A
  • IRD N/A
  • Revenue Growth
  • AKTX N/A
  • IRD N/A
  • 52 Week Low
  • AKTX $0.85
  • IRD $0.65
  • 52 Week High
  • AKTX $4.40
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 40.86
  • IRD N/A
  • Support Level
  • AKTX $1.11
  • IRD N/A
  • Resistance Level
  • AKTX $1.18
  • IRD N/A
  • Average True Range (ATR)
  • AKTX 0.05
  • IRD 0.00
  • MACD
  • AKTX -0.00
  • IRD 0.00
  • Stochastic Oscillator
  • AKTX 22.48
  • IRD 0.00

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: